Brexanolone to Treat Postpartum Depression in Adult Women.

Authors

Elyse M. Cornett, Louisiana State University Health Science Center
Lauren Rando, LSU Health Shreveport
Austin M. Labbé, LSU Health Shreveport
Wil Perkins, LSU School of Medicine
Adam M. Kaye, University of the PacificFollow
Alan David Kaye, Louisiana State University Health Science Center
Omar Viswanath, LSU Health Shreveport
Ivan Urits, Louisiana State University Health Sciences Center - Shreveport

ORCiD

Adam M. Kaye: 0000-0002-7224-3322

Document Type

Article

Publication Title

Psychopharmacology Bulletin

ISSN

2472-2448

Volume

51

Issue

2

First Page

115

Last Page

130

Publication Date

3-16-2021

Abstract

ZULRESSO (Brexanolone) is a novel FDA-approved treatment for moderate-to-severe postpartum depression. Postpartum depression may be diagnosed in women experiencing depressive symptoms which can manifest as cognitive, behavioral, or emotional disturbances as early as the third trimester to 4 weeks following delivery. The efficacy of brexanolone suggests that neurosteroids such as allopregnanolone are important to treat PPD. However, it is currently unclear if brexanolone provides lasting relief of depressive symptoms at or beyond 30 days following administration. Further studies are necessary to make this determination.

Recommended Citation

Cornett, E. M., Rando, L., Labbé, A. M., Perkins, W., Kaye, A. M., Kaye, A. D., Viswanath, O., & Urits, I. (2021). Brexanolone to Treat Postpartum Depression in Adult Women.. Psychopharmacology Bulletin, 51(2), 115–130.
https://scholarlycommons.pacific.edu/phs-facarticles/574